casino slots background
2025-01-09   

Newport News-based ivWatch receives accolades for life-saving technologyNoneBird Flu Found In Raw Milk Leads To Recall In Californiacasino slots background 。

Ana Navarro Mocked For Citing Fictional Pardon To Defend Joe BidenTC Energy Co. ( NYSE:TRP – Free Report ) (TSE:TRP) – Research analysts at National Bank Financial increased their FY2025 EPS estimates for shares of TC Energy in a research note issued on Tuesday, November 19th. National Bank Financial analyst P. Kenny now anticipates that the pipeline company will earn $2.84 per share for the year, up from their previous estimate of $2.78. The consensus estimate for TC Energy’s current full-year earnings is $2.98 per share. Several other brokerages also recently weighed in on TRP. JPMorgan Chase & Co. upgraded TC Energy from a “neutral” rating to an “overweight” rating in a report on Monday, October 14th. The Goldman Sachs Group raised their target price on shares of TC Energy from $38.00 to $42.00 and gave the company a “sell” rating in a report on Monday, October 21st. UBS Group raised shares of TC Energy from a “neutral” rating to a “buy” rating in a research report on Monday, September 30th. StockNews.com initiated coverage on shares of TC Energy in a research report on Monday, November 18th. They set a “hold” rating for the company. Finally, BMO Capital Markets increased their target price on TC Energy from $66.00 to $70.00 and gave the company a “market perform” rating in a report on Wednesday. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, TC Energy has an average rating of “Hold” and an average price target of $55.67. TC Energy Stock Down 0.7 % Shares of NYSE TRP opened at $49.86 on Friday. The stock has a market cap of $51.75 billion, a P/E ratio of 13.81, a PEG ratio of 4.19 and a beta of 0.81. The business’s fifty day simple moving average is $47.22 and its 200-day simple moving average is $43.18. TC Energy has a 12-month low of $31.83 and a 12-month high of $50.37. The company has a current ratio of 1.31, a quick ratio of 1.23 and a debt-to-equity ratio of 1.78. TC Energy ( NYSE:TRP – Get Free Report ) (TSE:TRP) last issued its quarterly earnings results on Thursday, November 7th. The pipeline company reported $0.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.70 by $0.06. The business had revenue of $2.99 billion for the quarter, compared to analysts’ expectations of $2.83 billion. TC Energy had a net margin of 31.15% and a return on equity of 12.92%. Hedge Funds Weigh In On TC Energy Large investors have recently modified their holdings of the business. Fortitude Family Office LLC acquired a new stake in shares of TC Energy during the 3rd quarter valued at approximately $28,000. Blue Trust Inc. raised its holdings in TC Energy by 72.0% during the third quarter. Blue Trust Inc. now owns 638 shares of the pipeline company’s stock worth $30,000 after purchasing an additional 267 shares during the last quarter. EdgeRock Capital LLC purchased a new stake in TC Energy during the second quarter worth $25,000. Whittier Trust Co. of Nevada Inc. grew its holdings in TC Energy by 138.8% in the second quarter. Whittier Trust Co. of Nevada Inc. now owns 738 shares of the pipeline company’s stock valued at $28,000 after purchasing an additional 429 shares during the last quarter. Finally, Point72 DIFC Ltd purchased a new position in shares of TC Energy in the third quarter valued at $39,000. 83.13% of the stock is owned by hedge funds and other institutional investors. TC Energy Increases Dividend The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be given a dividend of $0.822 per share. The ex-dividend date is Tuesday, December 31st. This represents a $3.29 dividend on an annualized basis and a yield of 6.59%. This is an increase from TC Energy’s previous quarterly dividend of $0.70. TC Energy’s dividend payout ratio is presently 78.95%. TC Energy Company Profile ( Get Free Report ) TC Energy Corporation operates as an energy infrastructure company in North America. It operates through five segments: Canadian Natural Gas Pipelines; U.S. Natural Gas Pipelines; Mexico Natural Gas Pipelines; Liquids Pipelines; and Power and Energy Solutions. The company builds and operates a network of 93,600 kilometers of natural gas pipelines, which transports natural gas from supply basins to local distribution companies, power generation plants, industrial facilities, interconnecting pipelines, LNG export terminals, and other businesses. Featured Articles Five stocks we like better than TC Energy Are Penny Stocks a Good Fit for Your Portfolio? Tesla Investors Continue to Profit From the Trump Trade Best Aerospace Stocks Investing MicroStrategy’s Stock Dip vs. Coinbase’s Potential Rally Stock Average Calculator Netflix Ventures Into Live Sports, Driving Stock Momentum Receive News & Ratings for TC Energy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TC Energy and related companies with MarketBeat.com's FREE daily email newsletter .

Google parent Alphabet gets CCI's clearance to acquire stake in Flipkart, here's what the order saysWestern Georgia Wolves vs. Utah Valley Wolverines: How to watch online, live stream info, start time, TV channel

Filamon Limited, an Australian biotech company focused on developing next-gen anti-inflammatory drugs, has announced its breakthrough dementia treatment. ALPHA-003 is designed to preserve the integrity of vital brain cell structures and protect them against destruction caused by brain inflammation. In healthy neurons, the tau protein stabilizes , crucial tube-like structures that, together with neurofilaments, maintain the neurons’ shape and provide mechanical support. However, when it’s modified, tau can form – tangles that degrade these key structures. This is seen in a group of diseases called tauopathies, such as dementia, including Alzheimer’s disease, and (CTE). Existing dementia treatments focus on reducing the consequences of this structural damage but have enjoyed only moderate success. Now, an Australian biotech company, Filamon Limited, has announced its breakthrough treatment, , which is aimed at halting the progression of dementia by preventing microtubular destruction. “The underlying problem with most forms of dementia is the destruction of a key structural component of brain cells known as microtubules,” said Associate Professor Kieran Scott, Professor of Oncology at Western Sydney University, and co-founder of Filamon. “These long, hollow tubes are vital to healthy brain function. In dementia, these microtubules degrade, resulting in the death of brain cells. “To date, no one has found a way of preventing microtubular destruction,” Scott said. “We believe ALPHA-003 has the potential to be that first drug by stabilizing the two main brain cell components whose job is to protect microtubules from damage – tau and neurofilaments.” ALPHA-003 is designed to prevent damaging brain inflammation by binding to tau and neurofilaments, providing the microtubular protection that Scott is referring to. The result of deep-learning, computational drug design technology developed in Australia, ALPHA-003 started life as a more general anti-inflammatory drug, countering the effects of human group IIA secretory phospholipase A (hGIIA), a significant player in inflammatory conditions, before its developers realized its potential for treating neuroinflammation, specifically. “ALPHA-003 was under development as a new form of anti-inflammatory drug that worked by blocking the activating effects of the key inflammatory ligand, hGIIA, on a range of cell structural proteins,” Professor Graham Kelly, Filamon’s co-founder, CEO, and Managing Director said in an interview with . “Activation of those proteins underlies most chronic inflammatory changes. Recent published data has shown that tau is another structural protein that responds to hGIIA, so we simply asked the question whether ALPHA-003 would have the same protective effect on tau. Our studies showed that it does, to the extent of blocking the ability of tau to form sheets of oligomers that comprise the ‘tau neurofibrillary tangles.’” But it wasn’t just the need to fill a treatment niche that drove the drug’s development. Kelly explained to that experiencing the devastating effects of dementia first-hand was also a motivating factor. “The personal angle has been the confronting experience of seeing a very good friend who has always been a bundle of energy and force of nature deteriorate into a tragic, sunken, shell of a woman who has lost all recognition of friends and family,” he said. But does ALPHA-003 work? Pre-clinical studies strongly suggest that it does. Importantly, the drug has been found to cross the blood-brain barrier in mammals, meaning it can exert a direct effect on brain cells. The team at Filamon were so happy with the results that they announced them prior to journal publication. “The announced news is literally freshly generated,” Kelly told . “We considered it to be of such importance to warrant being released pre-publication. More studies are underway, and the results of those studies will be the subject of journal submissions.” Kelly foresees ALPHA-003 being used to treat dementia at the time of diagnosis. “We see dementia as a two-step process involving (i) creation of an ongoing neuroinflammatory trigger, and (ii) the consequences of that trigger,” he told . “ALPHA-003 is aiming at blocking the latter, but that requires accepting that the underlying neuroinflammation trigger continues unabated. ALPHA-003 simply is aiming to mitigate the effects of the trigger. Another Filamon experimental drug program underway with another drug technology aims to deactivate this trigger.” Filamon aims to have ALPHA-003 available for use in 2026. It’s expected that the drug will treat tauopathies other than the two major forms of dementia – Alzheimer’s disease and frontotemporal dementia – such as progressive supranuclear palsy, an uncommon Parkinson’s-like disorder, and CTE, caused by repeated concussions. Source: [PDF]Best Holiday Gift Ideas for the Photographer in Your LifeThe UN nuclear watchdog's board of governors passed a resolution chiding Iran's poor cooperation with the agency after hours of heated exchanges, diplomats told AFP late on Thursday, a move Tehran called "politically motivated". The censure motion brought by Britain, France, Germany and the United States at the International Atomic Energy Agency's 35-nation board follows a similar one in June. But it comes as tensions run high over Iran's atomic programme, with critics fearing that Tehran is attempting to develop a nuclear weapon -- a claim the Islamic Republic has repeatedly denied. The resolution -- which China, Russia and Burkina Faso voted against -- was carried by 19 votes in favour, with 12 abstentions and Venezuela not participating, two diplomats told AFP. Ahead of the vote on Thursday night, the United States and its European allies sought to rally support for their resolution by denouncing Iran. In its national statement to the board, Washington said that Tehran's nuclear activities are "deeply troubling". London, Paris and Berlin in a joint statement drew attention to the "threat" Iran's nuclear programme posed "to international security", stressing that it now had enough highly enriched uranium for four nuclear weapons. In a first reaction after the vote, Iran's ambassador to the IAEA, Mohsen Naziri Asl, told AFP that the resolution was "politically motivated", citing its "low support" compared to previous censures. The confidential resolution seen by AFP says it is "essential and urgent" for Iran to "act to fulfil its legal obligations". The text also calls on Tehran to provide "technically credible explanations" for the presence of uranium particles found at two undeclared locations in Iran. Moreover, Western powers are asking for a "comprehensive report" to be issued by the IAEA on Iran's nuclear efforts "at the latest" by spring 2025. Since 2021, Tehran has significantly decreased its cooperation with the agency by deactivating surveillance devices to monitor the nuclear programme and barring UN inspectors. At the same time, Iran has rapidly ramped up its nuclear activities, including by increasing its stockpiles of enriched uranium. That has heightened fears that Tehran might be seeking to develop a nuclear weapon, which it denies. The resolution comes just as IAEA head Rafael Grossi returned from a trip to Tehran last week, where he appeared to have made headway. During the visit, Iran agreed to an IAEA demand to cap its sensitive stock of near weapons-grade uranium enriched up to 60 percent purity. "This is a concrete step in the right direction," Grossi told reporters Wednesday, saying it was "the first time" Iran had made such a commitment since it started breaking away from its obligations under the nuclear deal. The landmark 2015 deal -- which curbed Iran's nuclear programme in exchange for sanctions relief -- fell apart three years later after the unilateral withdrawal by the United States under then-president Donald Trump. In retaliation, Tehran began gradually rolling back some of its commitments by increasing its uranium stockpiles and enriching beyond the 3.67 percent purity -- enough for nuclear power stations -- permitted under the deal. Although symbolic in nature at this stage, the censure motion is designed to raise diplomatic pressure on Iran. Iran's Foreign Minister Abbas Araghchi said Thursday the censure "will disrupt" interactions with the agency, but stressed Tehran would remain keen to cooperate. Earlier, Araghchi had warned of a "proportionate" response by Iran if the board passes the resolution. According to Heloise Fayet, a researcher at the French Institute of International Relations, the resolution has the potential to "harm Rafael Grossi's efforts". "But Western powers are frustrated by the lack of effectiveness of his diplomatic manoeuvres and are looking for firmer solutions," she told AFP. On Wednesday, Grossi said he could "not exclude" that Iran's commitment to cap enrichment might falter "as a result of further developments". Foreign policy expert Rahman Ghahremanpour said Tehran might retaliate to the new censure by "increasing the enrichment levels". But he does not expect any drastic "strategic measures" as Iran does not want to "aggravate tensions" before Trump returns to the White House. pdm-anb-kym/giv

Related hot word search:

Previous: casino slots las vegas
Next: download free casino slots